Institute for Global Health and Wellbeing
The UCLan Research Institute for Global Health and Wellbeing (LIFE) brings together researchers from across the University to enhance and enable health and wellbeing research that is globally relevant.
In line with UCLan’s research and internationalisation strategies, the Institute will create new global health research collaborations to support those that already exist. This will enable us to reach more people, build our reputation and have a positive impact.
It will achieve this through a range of activities:
- Support researchers to develop high-quality funding applications.
- Deliver research programmes.
- Encourage researchers at all stages of their careers to engage at a global level.
The Institute, led by Professor Dame Caroline Watkins, began in Jan 2018, with the support of key staff Professor StJohn Crean, Rachel Georgiou and Professor Cathy Jackson.
News and events
Better Outcomes for Everybody (BOFE)
The prevalence of asthma has been increasing, and about 400 million people will have asthma by 2025. Chronic Obstructive Pulmonary Disease (COPD) was the fourth leading cause of death worldwide in 2015 and will become the third by 2030. Asthma accounts for an economic loss of €72 billion and COPD of €141 billion annually in 28 countries of the European Union.
A previous study conducted in Italy demonstrated the effectiveness and cost-effectiveness of a pharmacist-led intervention for Asthma patients but not for patients suffering from COPD.
BOFE is an international multicentre randomised controlled trial, funded by SOFAD Gruppo Farvima, that evaluates the effectiveness and cost-effectiveness of a bespoke pharmacist-led intervention for Asthma and COPD patients using Artificial Intelligence (AI) and the Internet of Medical Things (IoMT).
All patients in the intervention arm will receive a bespoke pharmacist-led intervention. Some will receive more intensive monitoring based on AI and IoMT. Patients in the control arm will receive standard care.
The outcomes of the study are intended to improve clinical conditions, quality of life, adherence to medication treatments, and medicine optimisation. This in turn should improve health outcomes and reduce costs to the NHS and the society.